| Literature DB >> 19669322 |
Seung Up Kim1, Sang Hoon Ahn, Jun Yong Park, Do Young Kim, Chae Yoon Chon, Jin Sub Choi, Kyung Sik Kim, Kwang-Hyub Han.
Abstract
BACKGROUND: Liver stiffness measurement (LSM) using transient elastography (FibroScan((R))) reflects the degree of hepatic fibrosis. This prospective study investigated how well LSM predicts the development of hepatic insufficiency after curative liver resection surgery for hepatocellular carcinoma.Entities:
Year: 2008 PMID: 19669322 PMCID: PMC2716908 DOI: 10.1007/s12072-008-9091-0
Source DB: PubMed Journal: Hepatol Int ISSN: 1936-0533 Impact factor: 6.047
Patient baseline characteristics (n = 72)
| Variables | |
|---|---|
| Male | 56 (72.2%) |
| Age (years) | 54.9 ± 10.6 |
| Background liver diseasea | |
| CHB/child A cirrhosis/child B cirrhosis | 20 (27.7%)/44 (61.1%)/8 (11.2%) |
| Body mass index (kg/m2) | 24.0 ± 2.8 |
| White blood cell count (103/μl) | 5,740 (2,420–26,930) |
| Hemoglobin (g/dl) | 14.1 ± 1.5 |
| Platelet count (109/l) | 154.2 ± 72.8 |
| Total protein (mg/dl) | 7.0 ± 1.1 |
| Albumin (mg/dl) | 4.1 ± 0.7 |
| Total bilirubin (mg/dl) | 1.2 ± 0.6 |
| AST (IU/l) | 48.5 ± 49.3 |
| ALT (IU/l) | 49.3 ± 40.9 |
| Cholesterol (mg/dl) | 150.2 ± 32.2 |
| Gamma glutamyltranspeptidase (IU/l) | 63.4 ± 70.5 |
| Alkaline phosphatase (IU/l) | 95.6 ± 45.2 |
| Prothrombin time (%) | 90.0 ± 9.5 |
| Alpha-feto protein (ng/ml) | 15.5 (2.6–39,879.7) |
| <20 | 41 (56.9%) |
| <400 and ≥20 | 17 (23.6%) |
| ≥400 | 14 (19.5%) |
| Spleen size (cm) | 10.8 ± 2.29 |
| ICG R15 (%) | 11.8 ± 7.1 |
| Liver stiffness/IQR (kPa)/SR | 17.1 ± 11.2/1.7 ± 0.8/88.8% |
CHB, chronic hepatitis B; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ICG R15, indocyanine green retention at 15 min; IQR, interquartile range; SR, success rate
aBackground liver disease was defined after surgery
Operation and tumor characteristics (n = 72)
| Variables | |
|---|---|
| Etiology | |
| HBV/HCV/non-B and non-C | 60 (83.3%)/9 (12.5%)/3 (4.2%) |
| Operation method | |
| Segmentectomy | 12 (16.6%) |
| Bisegmentectomy | 16 (22.2%) |
| Trisegmentectomy | 0 (0.0%) |
| Lobectomy | 44 (61.2%) |
| Right/left/central | 28/12/4 |
| Blood loss (cc) | 800 (10–8,100) |
| Operation time (min) | 341.4 ± 147.9 |
| Tumor size (cm) | 3.32 ± 1.82 |
| Tumor number | |
| One | 65 (90.2%) |
| Two | 7 (9.8%) |
| Tumor site | |
| Right | 37 (51.4%) |
| Left | 33 (45.8%) |
| Both | 2 (2.8%) |
| Tumor stagea | |
| Stage I | 9 (12.5%) |
| Stage II | 56 (77.7%) |
| Stage III | 7 (9.8%) |
HBV, hepatitis B-virus; HCV, hepatitis C-virus
aTumor stage is expressed according to the modified UICC staging system
Comparison between patients without and with postoperative hepatic insufficiency
| Variables | Patients without hepatic insufficiency ( | Patients with hepatic insufficiency ( | |
|---|---|---|---|
| Age (years) | 55.3 ± 10.3 | 52.9 ± 12.6 | 0.580 |
| Liver stiffness (kPa) | 15.1 ± 10.5 | 26.8 ± 9.5 | 0.010 |
| AST (IU/l) | 51.1 ± 53.6 | 35.4 ± 10.5 | 0.448 |
| ALT (IU/l) | 51.9 ± 44.0 | 36.1 ± 15.6 | 0.358 |
| Albumin (mg/dl) | 4.15 ± 0.68 | 4.13 ± 0.90 | 0.229 |
| Total bilirubin (mg/dl) | 1.19 ± 0.59 | 1.34 ± 0.98 | 0.292 |
| Prothrombin time (%) | 90.1 ± 9.7 | 89.4 ± 9.2 | 0.858 |
| Platelet (109/L) | 159.4 ± 66.1 | 128.6 ± 102.7 | 0.313 |
| ICG R15 (%) | 11.3 ± 7.0 | 14.2 ± 7.5 | 0.317 |
| Blood loss (cc) | 1,222.1 ± 1,418.3 | 2,028.6 ± 2,751.2 | 0.258 |
| Operation time (min) | 322.6 ± 125.2 | 435.7 ± 219.5 | 0.229 |
| Tumor size (cm) | 3.42 ± 1.86 | 2.84 ± 1.63 | 0.453 |
| Tumor stage I/II/III ( | 8/51/6 | 1/5/1 | 0.170 |
| <lobectomy vs. ≥lobectomy ( | 27/38 | 1/6 | 0.010 |
ALT, alanine aminotransferase; ICG R15, indocyanine green retention at 15 min
a25.6 kPa of liver stiffness and 12.0% of ICG R15 are the cutoff of best accuracy
Fig. 1The ROC curves of LSM and ICG R15 for predicting postoperative hepatic insufficiency (0.824 and 0.620, respectively)
Logistic regression analysis of risk factors associated with postoperative hepatic insufficiency after hepatectomy
| Variables | Odds ratio | ||
|---|---|---|---|
| Univariate | Multivariate | ||
| Gender | |||
| Male vs. female | 0.247 | – | |
| Age (years) | |||
| <55 vs. ≥55 | 0.885 | – | |
| Background liver disease | |||
| Noncirrhosis vs. cirrhosis | 0.099 | 0.922 | 1.214 |
| Body mass index (kg/m2) | |||
| <30 vs. ≥30 | 0.308 | – | |
| Child-Pugh class | |||
| A vs. B | 0.434 | – | |
| Total bilirubin (mg/dl) | |||
| <1.2 vs. ≥1.2 | 0.337 | – | |
| Albumin (mg/dl) | |||
| <4.0 vs. ≥4.0 | 1.000 | – | |
| ALT (IU/l) | |||
| <50 vs. ≥50 | 0.308 | – | |
| Cholesterol (mg/dl) | |||
| <150 vs. ≥150 | 0.415 | – | |
| Prothrombin time (%) | |||
| <90 vs. ≥90 | 0.836 | – | |
| Tumor stage | |||
| Stage I vs. stages II and III | 0.836 | – | |
| Stage I and II vs. stage III | 0.434 | – | |
| Type of resection | |||
| <Lobectomy vs. ≥lobectomy | 0.142 | – | |
| Operative bleeding (ml) | |||
| <1,350 vs. ≥1,350 | 0.604 | – | |
| Operative time (min) | |||
| <340 vs. ≥340 | 0.783 | – | |
| Blood transfusion | |||
| Yes vs. no | 0.675 | – | |
| Liver stiffness (kPa) | |||
| <25.6 vs. ≥25.6a | <0.001 | 0.001 | 19.140 |
| ICG R15 (%) | |||
| <10.0 vs. ≥10.0 | 0.415 | – | |
| <12.0 vs. ≥12.0a | 0.675 | – | |
| <15.0 vs. ≥15.0 | 0.753 | – | |